Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the transcript. The company has highlighted a strong balance sheet with a net cash position of approximately INR 284 crores. The acquisition of the Faridabad hospital is being funded through internal resources (corporate reserves and existing cash) without raising new debt. The company reported a significant reduction in finance costs due to prudent financial management and lower borrowing expenses. No statements indicate plans for issuing equity or raising additional debt for ongoing or future expansions.

Any current/future capex/capital investment/strategic investment?

Acquisition of Asian Fidelis Hospital (200-bed super specialty hospital in Faridabad) for INR 1,160 million, expected to complete by March 2024; hospital ready to be operationalized immediately. Brownfield expansion plans: - Greater Noida Hospital bed capacity to increase from 400 to 600 beds. - Noida Extension Hospital bed capacity to increase from 450 to 700 beds. Acquired land parcels adjacent to both Greater Noida and Noida Extension hospitals for expansion. Expected capex per bed for expansions around INR 70 lakhs. Construction/ramp-up to commence soon, with weather improvement in Del

Future growth expectations in sales/revenue/volumes?

Revenue grew 21% year-on-year in Q3, reflecting robust growth across specialties. Nine months FY24 revenue increased 31% year-over-year. Revenue growth driven by higher ARPOB and increased complexity of procedures. Bed occupancy improved to 52%-53%, expected to rise further with seasonal trends ending. Oncology revenue surged more than tenfold YoY; gastroenterology, pulmonology, nephrology, urology, and cardiology also posted strong growth. Expansion plans include doubling bed capacity, especially in Noida Extension and Greater Noida hospitals, to optimize occupancy. Addition of new specialtie

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth momentum remains robust; Q3 FY24 revenue increased 21% YoY and 6% QoQ. EBITDA margins expanded to 27.8% in Q3 FY24, up 160 bps YoY and 123 bps QoQ; margins expected to be sustainable. Profit after tax increased 39% YoY in Q3 FY24 and 57% YoY in nine months FY24 period. Occupancy rate improving (52%-55% group level), with individual hospitals like Greater Noida at 65%-70%. ARPOB (Average Revenue per Occupied Bed) growing steadily at 14% YoY, driven by higher complexity procedures. Ramp-up of newer hospitals like Jhansi expected to increase margins progressively. Medical tourism a

Yatharth Hospit.Q3 FY24Healthcare Services

Yatharth Hospit. Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,034P/E: 59.6Market Cap: ₹10.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Revenue grew 21% year-on-year in Q3, reflecting robust growth across specialties.
Nine months FY24 revenue increased 31% year-over-year.
Revenue growth driven by higher ARPOB and increased complexity of procedures.
Bed occupancy improved to 52%-53%, expected to rise further with seasonal trends ending.
Oncology revenue surged more than tenfold YoY; gastroenterology, pulmonology, nephrology, urology, and cardiology also posted strong growth.
Expansion plans include doubling bed capacity, especially in Noida Extension and Greater Noida hospitals, to optimize occupancy.
Addition of new specialties such as radiation and robotic surgeries to attract more patients.
Medical tourism focus expected to significantly boost ARPOB and revenues.
Anticipate reaching optimized utilization in newer hospitals within 2-3 years, contributing to volume and revenue growth.
Continued infrastructure upgrades at hospitals to enhance patient experience and competitiveness.

Margin guidance

Category 3

Revenue growth momentum remains robust; Q3 FY24 revenue increased 21% YoY and 6% QoQ.
EBITDA margins expanded to 27.8% in Q3 FY24, up 160 bps YoY and 123 bps QoQ; margins expected to be sustainable.
Profit after tax increased 39% YoY in Q3 FY24 and 57% YoY in nine months FY24 period.
Occupancy rate improving (52%-55% group level), with individual hospitals like Greater Noida at 65%-70%.
ARPOB (Average Revenue per Occupied Bed) growing steadily at 14% YoY, driven by higher complexity procedures.
Ramp-up of newer hospitals like Jhansi expected to increase margins progressively.
Medical tourism and super-specialty expansion expected to contribute significantly to revenue and margins.
Expansion plans including bed capacity doubling aligned with anticipated capacity optimization within 2-3 years.
EBITDA positive operations expected for new acquisitions and expansions within 2 years, supporting overall profitability.

See what Yatharth Hospit. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

There is no mention of any current or planned new fundraising through debt or equity in the transcript.
The company has highlighted a strong balance sheet with a net cash position of approximately INR 284 crores.
The acquisition of the Faridabad hospital is being funded through internal resources (corporate reserves and existing cash) without raising new debt.
The company reported a significant reduction in finance costs due to prudent financial management and lower borrowing expenses.
No statements indicate plans for issuing equity or raising additional debt for ongoing or future expansions.
The focus remains on organic and inorganic expansion financed through existing cash reserves and internal accruals.

Order book

The transcript provided does not explicitly mention details about the current or expected order book or pending orders for Yatharth Hospitals and Trauma Care Services Limited. The discussion primarily focuses on operational metrics, hospital expansions, occupancy rates, financial performance, and strategic initiatives such as acquisitions and infrastructure upgrades. No specific data or commentary on order books or pending orders is available in the provided pages.

See what Yatharth Hospit. management said on order book — free account, 30 seconds.

Capex plans

Yes

Acquisition of Asian Fidelis Hospital (200-bed super specialty hospital in Faridabad) for INR 1,160 million, expected to complete by March 2024; hospital ready to be operationalized immediately.
Brownfield expansion plans:
- Greater Noida Hospital bed capacity to increase from 400 to 600 beds.
- Noida Extension Hospital bed capacity to increase from 450 to 700 beds.
Acquired land parcels adjacent to both Greater Noida and Noida Extension hospitals for expansion.
Expected capex per bed for expansions around INR 70 lakhs.
Construction/ramp-up to commence soon, with weather improvement in Delhi NCR cited as a factor for starting.
Strategic focus on doubling bed capacity over the next three years through a combination of greenfield and brownfield expansions.
No debt financing planned for the Faridabad acquisition; to be funded from cash reserves and corporate reserves.

Track Yatharth Hospit. — get its next earnings analysis in your feed

How does Yatharth Hospit. rank vs peers in Healthcare Services?

Pro feature

ThisYatharth Hospit.

Rev 2Mar 3

See where Yatharth Hospit. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Yatharth Hospit. rank in Healthcare Services?

Compare Yatharth Hospit. against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Yatharth Hospit.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →